Last reviewed · How we verify
Calcitriol Cream
Calcitriol Cream, marketed by Merck Sharp & Dohme LLC, holds a position in the dermatological segment with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the strong brand recognition of Merck. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Calcitriol Cream |
|---|---|
| Also known as | Vectical Ointment |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022) (PHASE1)
- Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcitriol Cream CI brief — competitive landscape report
- Calcitriol Cream updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI